Rational approach to the treatment of EGFR-positive lung cancer
Molecularly targeted therapy with tyrosine kinase inhibitors (TKI) has been recognized as the optimal treatment option for patients with EGFR-positive non-small-cell lung cancer (NSCLC). At present, 5 drugs of this group are available: first generation – erlotinib and gefitinib, second generation –...
Shranjeno v:
| Principais autores: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Russo |
| Izdano: |
Remedium Group LLC
2019-12-01
|
| Serija: | Медицинский совет |
| Teme: | |
| Online dostop: | https://www.med-sovet.pro/jour/article/view/5146 |
| Oznake: |
Brez oznak, prvi označite!
|